Immunic Reports Completion of Patient Enrollment in P-II CALDOSE-1 Trial of IMU-838 for the Treatment of Ulcerative Colitis
Shots: The company has completed the enrolment in the P-II CALDOSE-1 trial to evaluate the efficacy & safety of IMU-838 (10/30/45mg, PO) vs PBO in 263 patients with mod. to sev. UC at 100+ sites in 19 countries including the US & EU. The results are expected in Q2’22 The 1EPs of the trial include […]